The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells

Cyril Bourouh, Émilie Courty, Laure Rolland, Gianni Pasquetti, Xavier Gromada, Nabil Rabhi, Charlène Carney, Maeva Moreno, Raphaël Boutry, Émilie Caron,

Cell Reports · 2022 · 15 citations · 57 references

DOIFull text

Open access

Concepts

Abstract

The glucagon-like peptide 1 (Glp-1) has emerged as a hormone with broad pharmacological potential in type 2 diabetes (T2D) treatment, notably by improving β cell functions. The cell-cycle regulator and transcription factor E2f1 is involved in glucose homeostasis by modulating β cell mass and function. Here, we report that β cell-specific genetic ablation of E2f1 ( E2f1 β−/− ) impairs glucose homeostasis associated with decreased expression of the Glp-1 receptor ( Glp1r ) in E2f1 β−/− pancreatic islets. Pharmacological inhibition of E2F1 transcriptional activity in nondiabetic human islets decreases GLP1R levels and blunts the incretin effect of GLP1R agonist exendin-4 (ex-4) on insulin secretion. Overexpressing E2f1 in pancreatic β cells increases Glp1r expression associated with enhanced insulin secretion mediated by ex-4. Interestingly, ex-4 induces retinoblastoma protein (pRb) phosphorylation and E2f1 transcriptional activity. Our findings reveal critical roles for E2f1 in β cell function and suggest molecular crosstalk between the E2F1/pRb and GLP1R signaling pathways.

References

57